Share on StockTwits
 

Novo Nordisk (NYSE:NVO) was upgraded by stock analysts at Bank of America from a “neutral” rating to a “buy” rating in a report issued on Tuesday, Stock Ratings Network reports.

A number of other firms have also recently commented on NVO. Analysts at JPMorgan Chase & Co. upgraded shares of Novo Nordisk from an “underweight” rating to an “overweight” rating in a research note on Monday. Separately, analysts at Zacks downgraded shares of Novo Nordisk from an “outperform” rating to a “neutral” rating in a research note on Monday, February 10th. They now have a $45.00 price target on the stock. Finally, analysts at Swedbank upgraded shares of Novo Nordisk from a “neutral” rating to a “buy” rating in a research note on Friday, January 31st. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $487.50.

Shares of Novo Nordisk (NYSE:NVO) opened at 45.82 on Tuesday. Novo Nordisk has a 52 week low of $29.898 and a 52 week high of $46.25. The stock’s 50-day moving average is $40.33 and its 200-day moving average is $36.04. The company has a market cap of $121.6 billion and a P/E ratio of 28.23.

Novo Nordisk (NYSE:NVO) last announced its earnings results on Tuesday, January 28th. The company reported $0.42 EPS for the quarter. On average, analysts predict that Novo Nordisk will post $1.90 earnings per share for the current fiscal year.

Novo Nordisk A/S is a Denmark-based health care company. It also focuses within areas, such as haemostasis management, growth hormone therapy and hormone replacement therapy.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.